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April 25, 2019, National DNA Day in the USA, commemorates the discovery of the DNA double helix in 1953 and the completion of the Human Genome Project in 2003. This double celebration shows how the early findings of Watson, Crick, Wilkins and Franklin marked the beginning of the genomics era.

The Human Genome Project was a US\$3 billion, 15-year-long, publicly funded project initiated in 1990. Its completion would probably have taken much longer without the appearance on the scene, in 1998, of Craig Venter's private enterprise, Celera Genomics. This event generated a public--private rivalry, leading to a race to sequence the human genome. The direct competition between the public and the private sector, which started at the dawn of genomics, continues to exist, but has also evolved into partnership models in efforts to roll out genomic medicine into health-care systems.

It is hard to imagine that the end goal of the world\'s largest collaborative biological project can now be achieved in under an hour and for less than US\$150.

Information about a person's genetic data is now easily available, and many private companies offer a variety of screenings that provide different types of information. It is possible to request genotyping for a specific region of the DNA that determines a small fraction of an individual's genome, but partial (whole exome sequencing) or whole genome sequencing are also offered. These enterprises generate a great deal of diversified data regarding human genomes, but are we ready to handle that information properly?

On March 20, 2019, UK health secretary Matt Hancock, after taking a commercial genetic test that revealed a heightened risk of developing prostate cancer, called for predictive testing to be run by the National Health Service. This statement, however, met with criticism and controversy, as such tests can be highly overstated and misinterpreted, causing unnecessary anxiety and a waste of resources if not handled properly.

Individuals seek genetic and genomic testing or pre-birth tests because they desire a healthy life for themselves and their children. They want to have the chance to know how to prevent diseases, which medications should be avoided, and what are the probabilities of having a genetic condition. Genetic and genomic testing can indeed identify genetic variants linked to disease and constitute one of the best examples of the evolution of personalised medicine. However, are such tests able to meet these high expectations?

While obtaining test results is easy, interpreting those results is not simple, and Hancock's recent story highlights how fundamental it is to maintain caution. We still have a very limited knowledge and understanding of disease variants, especially regarding their participation in disease risk and causality. For most disease-associated variants, we don't know whether their role is good, bad, or neutral; therefore, being aware of which variants an individual carries is often of little, if any, help. Solid genetic counselling is necessary to give the correct perspective and to make good use of the data. Doctors and geneticists have to be prepared to manage expectations, and to ensure that patients are aware that a genetic test does not provide a black-or-white answer. Each prediction, indeed, is linked to a level of uncertainty that varies depending on the type of test and type of disease under consideration -- interpreting results for monogenic disorders may be easier than for polygenic disorders -- and that has to be considered when making decisions.

Another grey area relates to the ownership of the data. Most users give consent to genomics companies to use the data for research purposes, but it is still difficult to set boundaries. The field is rapidly evolving, and it can be unclear which specific research uses the data might serve in the future. Nevertheless, consumers need to be fully aware of what they are agreeing to, what their rights are, and how their personal data will be protected. It is a complicated issue, and better and clearer policies are required to ensure maximal transparency.

From a wider perspective, understanding the genomic data of a population can help develop a better health-care system. The UK government recognises such value and, in December, 2012, launched the 100,000 Genomes Project, which, overseen by Genomics England, sequenced whole genomes from NHS patients with a focus on rare diseases, some common types of cancer, and infectious diseases. The project, which was once described as "building the plane whilst flying it", aimed to create the infrastructure for genomic medicine, as well as simultaneously delivering results. Its goals are multifaceted, ranging from fostering the UK genomics industry, producing a real and lasting change to NHS care, and providing results to participants. The project relies upon collaboration between health-care professionals, funders, industry and patients, and some benefits are already visible for patients, as one in four participants with rare diseases received a diagnosis for the first time. The establishment of the Participant Panel in 2016, chaired by Jillian Hastings Ward, is a sign of the so-called "people-powered health-care": only trust by patients, indeed, can ensure the successful advent and exploitation of new technologies and data.

The project was completed in December, 2018: this was an important milestone, but it is just the first step of an expanding initiative. The success of this venture moved the ambition forward, and the NHS's new goal is to sequence 5 million genomes in the UK over the next 5 years. To further implement the process of obtaining data from the general population, it will be now possible for healthy people to pay the NHS to sequence their genes on the condition that they share their data.

These events clearly signal a wave of change that will lead to a whole new conception of medicine and diagnosis. On February 27, 2019, Baroness Nicola Blackwood, the minister in charge of rare diseases, announced the development of a National Genomic Healthcare Strategy. Through the NHS Long Term Plan, this strategy aims to lead the world in the use of data and technology to prevent illness -- not just treat it. The NHS Genomic Medicine Service is the first national genomic health-care service in the world to provide whole genome sequencing for critically ill children with a suspected genetic condition, including cancers, and for any adults with certain rare diseases or hard-to-treat cancers.

Although it is exciting to look at the start of a novel way to consider health care, the path is still long before genome screenings become a standard care practice worldwide: time is needed for other countries to develop similar public health services, and for clinician and scientists to properly handle, use, and interpret the data.

On the occasion of DNA Day, many educational and scientific events are taking place across the globe: this is a great opportunity to reach out to the public, to appreciate the achievements of genomics research and technology, but also to inform people of risks and benefits that come with genomics integration into healthcare.

*EClinicalMedicine* is eager to engage the community to contribute to this debate and is looking for mindful advances in the field of clinical genomics, to help contribute to the creation of new health-care systems that will ultimately help us to live a better, healthier life.
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